Category: Philips Healthcare
A federal appeals court upholds the U.S. Patent & Trademark Office's decision not to review 8 defibrillator patents owned by Philips Healthcare and dismisses the case.
Here's a look at some of the top regulatory stories for medical device companies this week: Philips wins FDA nod for 3D TAVI planning software; Direct Flow wins CE Marks for TAVI device; FDA OKs return of Covidien's Pipeline embolism device; FDA delays UDI rule for contacts, intraocular lenses; Cardiovascular Systems recalls some Diamondback devices on embolism risk
Philips Healthcare wins 510(k) clearance from the FDA for its 3D planning software for transcatheter aortic valve implants.
Dentsply and Philips Healthcare land contracts worth a collective $39 million from the U.S. Defense Dept.
Zoll Medical and Philips Healthcare add a chapter to their 4-year-old battle over automated external defibrillator technology, withdrawing the appeal of Zoll's April loss in the patent infringement war.
Here's a look at some of the top Wall Street stories for medical device companies this week: Smith & Nephew CEO reveals new 'no frills' strategy; Bard: We're on track for early 2015 Lutonix approval; Ocular Therapeutix prices IPO below range; Philips' healthcare business suffers in Q2; Intersect ENT prices IPO at low end of range
Sluggish healthcare sales drag down Philips overall figures, but the company is eying a comeback for the 2nd half of the year.
Philips Healthcare (NYSE:PHG) had a tough 2nd quarter with a shutdown of a manufacturing facility in Cleveland taking some of the wind out of the sales for the entire company.